Showing results (461-470 of 484) with videos related to

Sort By:
Pageof 49
Radiology|November 1, 2002
Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease ResearchPeter A S Johnstone, Christopher J Kane, Leon Sun, et al.
Urology|May 12, 2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer programPeter Iversen, Manfred P Wirth, William A See, et al.
BJU International|November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancerFatima H Karzai, Andrea B Apolo, Liang Cao, et al.
Scientific Reports|March 31, 2022
Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progressionWilliam Gesztes, Cara Schafer, Denise Young, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2003
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease ResearchPeter A S Johnstone, Robert H Riffenburgh, Judd W Moul, et al.
Cancer Research|May 2, 2018
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell GrowthAhmed A Mohamed, Charles P Xavier, Gauthaman Sukumar, et al.
Genes & Cancer|February 14, 2017
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K GagAnshu Rastogi, Amina Ali, Shyh-Han Tan, et al.
The Journal of Urology|July 20, 2002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programWilliam A See, Manfred P Wirth, David G McLeod, et al.
Oncotarget|November 20, 2019
Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrenceWusheng Yan, Muhammad Jamal, Shyh-Han Tan, et al.
Oncogene|June 11, 2008
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiationC Sun, A Dobi, A Mohamed, et al.
Pageof 49